Tracking gene therapies

FDA's policies on long-term follow-up of participants in gene therapy trials involving retroviral vectors are unrealistic and should be replaced with a much less intensive set of requirements, members of the agency's Biological Response Modifiers Advisory Committee said on Friday.

The consensus of BRMAC members was that follow-up observation of gene therapy trial participants extending more than five years should be conducted or supported by government or a non-profit organization and should not be the responsibility of trial sponsors.

The committee did suggest that the categories of vectors requiring long-term follow-up should be expanded. It also provided guidance on the need to sequence viral vectors prior to Phase I trials and how FDA should respond to reports about the detection of gene therapy vectors in semen.

Although it was

Read the full 1281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers